Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1021-335X Online ISSN: 1791-2431
Journal Cover
March 2013 Volume 29 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
March 2013 Volume 29 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Photodynamic treatment induces cell death by apoptosis or autophagy depending on the melanin content in two B16 melanoma cell lines

  • Authors:
    • Agnès Sparsa
    • Solenn Bellaton
    • Thomas Naves
    • Marie-Odile Jauberteau
    • Jean-Marie Bonnetblanc
    • Vincent Sol
    • Mireille Verdier
    • Marie-Hélène Ratinaud
  • View Affiliations / Copyright

    Affiliations: EA 3842 Cellular Homeostasis and Pathology, Faculty of Medicine, University of Limoges, 87025 Limoges Cedex, France, Department of Dermatology, University Hospital Dupuytren, 87042 Limoges Cedex, France, Chemistry Laboratory of Natural Substances, Faculty of Sciences, 87060 Limoges Cedex, France
  • Pages: 1196-1200
    |
    Published online on: December 14, 2012
       https://doi.org/10.3892/or.2012.2190
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Photodynamic therapy (PDT) is now a well-established treatment modality for cutaneous carcinomas and is based on the administration of a light-activated drug followed by illumination of the pathological area. The treatment of metastatic melanoma remains a therapeutic challenge. To define the possible role of melanin in relative phototoxicity of 5-aminolevulinic acid (5-ALA), a photosensitizer used in PDT in vivo, we studied cell death in two variants (with or without melanin, B16F10 and B16G4F cells, respectively) of a melanoma cell line. Concentrations of 5-Ala up to 10 mM induced similar cytostatic effects in the B16G4F and B16F10 cells. PDT and high 5-ALA concentrations induced photocytotoxicity in both melanoma cell lines (at 10 mM for B16F10 cells and at 5 mM for B16G4F cells). Cell death corresponded to p53-dependent apoptotic signaling in pigmented B16F10 cells, whereas an autophagic response leading to a caspase-independent death was detected in non-pigmented B16G4F cells. Therefore, the PDT-induced cell death pathway appeared to correlate with melanin synthesis capacity in melanoma cells. To reduce the cytotoxicity of 5-ALA without irradiation, a low drug concentration could be used. Consequently, in combination with current therapeutics, a moderate concentration of 5-ALA and PDT may constitute a supplementary promising approach to eliminate metastatic melanoma.

Introduction

Photodynamic therapy (PDT) has been used in clinical application for many years, either systemically, or locally or topically applied to a patient bearing a lesion (cancerous or not). PDT with systemic photosensitizers has been used to treat a range of internal malignancies (lung and brain cancers) and for skin cancers (1). This cancer treatment is approved by many countries for the treatment of non-melanotic skin cancers such as basal cell carcinomas and Bowen's disease. PDT does not seem to be an appropriate treatment of melanotic melanoma in vivo, and several reasons can justify this low use. Almost all melanomas overexpress the classical ATP-binding cassette transporters (ABC protein family), leading to drug release into the extracellular medium and to the resistance by tumor cells. The antioxidant activity of melanoma is much higher than observed in other skin cancers (basal and squamous carcinomas) reducing the cytotoxic effect of ROS generated by PDT (2). Nearly all photosensitizers (PS) show a significant absorbance in ultraviolet (UV) wavelengths, while melanin absorbs a large portion of the light intended to activate PS. The light absorption by pigment strongly reduces its penetration into the tumor. Studies have been carried out with pigmented or amelanotic melanoma cells suggesting that amelanotic cells may be more susceptible to PDT (2). Among the molecules used in PDT, 5-aminolevulinic acid (5-ALA) is not itself a photosensitizer and instead it is used as a prodrug leading to the accumulation of protoporphyrin IX in the mitochondria inducing damage and subsequently cell death after light irradiation (3).

It is well-known that exposure of a photosensitizing agent to appropriate light leads to a photophysical reaction and the production of reactive oxygen species (ROS). These constitute the main driving force to initiate three types of cell death (necrosis, apoptosis or autophagy). Nevertheless, the signaling pathways involved in PDT-mediated cell death are not completely understood.

In this study, we examined the photocytotoxicity of 5-ALA on two variants of melanoma cell lines (pigmented B16F10 and amelanotic B16G4F cells), the cell death and autophagic pathways were investigated. One day after the induction of PDT with 5-ALA, the pan-caspase activity differed between the two melanoma cell lines. The recruitment of p53 and PUMA led to a caspase-dependent cell death in the pigmented cells whereas an autophagic cell death was activated in the non-pigmented (amelanotic) melanoma cells.

Materials and methods

Source and preparation of the photosensitizer

5-ALA (5-δ-aminolevulinic acid hypochloride) was obtained from Sigma-Aldrich Chimie (Saint-Quentin Fallavier, France) and prepared as a stable 30 mM stock solution (stored in aliquots at −80°C) from the lyophilized powder and was dissolved in Dulbecco's modified Eagle's medium (DMEM, Invitrogen-Fisher, Illkirch, France) containing 10% fetal bovine serum (FBS) (Invitrogen-Fisher). Other reagents are specified below.

Cell lines and culture conditions

The B16F10 pigmented melanoma cells were a gift from Dr Perron (Oncology Center, Toulouse, France). The amelanotic B16G4F melanoma cells (without Mc1r expression, the receptor of α-melanocyte stimulating hormone) were kindly provided by Professor A. Oulmouden (UMR INRA 1061, Limoges, France). Cells were grown to confluence in DMEM containing 10% FBS and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin) in a humidified 5% CO2 atmosphere at 37°C. The culture medium was renewed every 3 days. Cells were subcultured by dispersal with trypsin-EDTA and replated at 2×105/ml.

Light source

Exposure of melanoma cells to light was performed using either a red lamp composed of fluorescent tubes or light emitting diodes (LED) (Aktilite™ 128 Lamp, Galderma). The light fluence rate used by the red lamp was 37 mW/cm2 at 631 nm on the surface of the plate.

Irradiation protocol

Cells were seeded at 105 cells/ml in 96-well plates after trypsinization. After 24 h, the cells were washed twice with PBS and incubated with different concentration of 5-ALA (0, 2.5, 5, 10 or 20 mM) for 2 h with medium, in darkness and in a humidified 5% CO2 atmosphere at 37°C. The cells were then irradiated with the Aktilite Lamp™ at room temperature (25°C). The exposure time was adjusted to obtain 37 J/cm2 fluence (corresponding to ~8 min). In previous experiments, during cell illumination the temperature monitored at the top of the microplate was unchanged. Two controls were realized, one 96-well plate without photosensitizer and one with photosensitizer and without irradiation.

Cytotoxic and photocytotoxic studies

Cytotoxicity and photocytoxicity were measured using the XTT (3-(4,5-dimethyl- thiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay (Cell Proliferation Kit II, Roche Diagnostics, Meylan, France). Optical density is proportional to relative mitochondrial dehydrogenase activity and reflects cell viability. Three hours after the addition of 5-ALA, assays were performed at 0, 24 and 48 h either without irradiation or after the end of the irradiation. At the time of counting, 50 μl of DMEM without phenol red-XTT solution (0.3 mg/ml) was added and incubation was carried out for 3 h at 37°C. Optical density (OD) at 490 nm was determined (the OD reference at 690 nm was subtracted) in an MRX II (Dynex) absorbance reader. Cytotoxicity was evaluated by the OD ratio of treated vs. non-treated cells. Each value of XTT assay was obtained from cultures in triplicate.

Pan-caspase activity assay

Both melanoma cell lines were plated in a 24-well dish (Nunc) at 25×104 cells/well. After a 24-h culture, 5-ALA was added or not to the cells and irradiation was carried out according to the protocol. After incubation, cells were pooled and lysed in Chaps buffer. The assays were performed as previously described (4). Peptide substrates (Bachem, Germany) for pan-caspase (Z-VAD-AMC) were added to each well to a final concentration of 5×10−5 M. Pan-caspase (Z-VAD-CHO) inhibitors at 2.5 mM were added 30 min before the substrate. The assay plates were incubated at 37°C for 2 h and fluorescence was measured with a microplate reader (Twinkle LB 970, Berthold, France), then pan-caspase activities were expressed in relative fluorescence units (RFU). Background fluorescence was determined in wells containing Z-VAD-AMC assay mixture and substrate without cell lysates, and pan-caspase activity was expressed in relative units.

Western blotting

Protein lysates (30 μg) from ALA-treated or control B16F10 and B16G4F cells (2×106 cells/dish) were separated by SDS-PAGE. After electrophoretic migration, proteins were electroblotted onto cellulose membranes. After the blocking step (TBS-1X containing 0.1% Tween 20 and 5% non-fat dry milk) membranes were incubated with primary specific antibodies, recognizing the following antigens: rabbit anti-PUMA obtained from Cell Signaling (Ozyme, France), anti-cathepsin B (CA10) purchased from Abcam (France); tubulin (clone TU-02), beclin-1 (E-8) and MAP-LC3-II (H-50) and p53 (Bp53-12) obtained from Santa Cruz Biotechnology (Tebu-bio, France). They were revealed with appropriate secondary HRP-conjugated antibodies purchased from DakoCytomation (France). Blots were developed with Immobilon Western chemiluminescent HRP substrate from Millipore and analyzed with the G-Box (Ozyme). Each set of experiments was repeated independently for at least 3 times.

Results

Different levels of photocytotoxicity of 5-aminolevulinic in B16F10 and B16G4F murine melanoma cell lines

A time kinetic (0–48 h) study of cytotoxicity, measured with the XTT assay, corresponding to relative dehydrogenase activity (RDA), was carried out. Two series of experiments without or after red illumination were performed using 5, 10 and 20 mM of 5-ALA, respectively for the pigmented B16F10 melanoma cell line and with 2.5, 5 and 10 mM of 5-ALA for the amelanotic B16G4F melanoma cell line (Fig. 1). In both cell lines a similar cytostatic effect occured in relationship with 5-ALA concentrations. Nevertheless, after 48 h, the relative dehydrogenase activity increased in the non-irradiated cells. At 20 mM 5-ALA in the B16F10 cells the slowing of growth was not effective.

Figure 1

5-ALA and PDT induce photocytotoxicity and cytotoxicity in two melanoma murine cell lines. A cytotoxic effect appeared similar in relation to 5-ALA concentrations both in the pigmented B16F10 melanoma cell lines and in the amelanotic B16G4F melanoma cell line. The photocytotoxicity of 5-ALA appeared more intense in the amelanotic B16G4F cell line than that in the pigmented B16F10 cells. Cytotoxicity (with or without illumination) was measured using an XTT colorimetric assay proportional to the relative mitochondrial dehydrogenase activity which reflected cell viability. Three hours after the addition of 5-ALA (0–20 mM), assays were performed at 0, 24 and 48 h either without irradiation or after the end of the irradiation.

After photodynamic treatment (PDT) a moderate and transitional reduction in RDA was observed when compared to control cells at low 5-ALA concentrations; 5 mM for pigmented B16F10 and 2.5 mM for non-pigmented B16G4F cells, respectively (Fig. 1). For higher 5-ALA concentrations (10 mM for B16F10 and 5 mM for B16G4F cells, respectively) a significant photocytotoxicity was observed.

Pan-caspase activity in B16F10 and B16G4F cell lines after photodynamic treatment

In order to detect the apoptotic process after a 24-h cell irradiation, total caspase activity was measured with a peptide substrate recognized by all caspases (pan-caspase), and compared with the same experiments in the presence of a specific inhibitor (ZVAD-CHO). In pigmented B16F10 cells, the pan-caspase activity was significantly increased following addition of 10 mM 5-ALA in comparison with the action in the control cells (Fig. 2). In the B16G4F cells, no significant change was observed between the control conditions and cells after PDT in combination with 5 mM 5-ALA. At high 5-ALA concentrations (20 mM for B16F10 cells and 10 mM for B16G4F cells, respectively), a drastic disappearance in caspase activity was detected corresponding to cell death at 24 h.

Figure 2

5-ALA and PDT induce a caspase-dependent- and caspase-independent cell death in the two melanoma murine cell lines. A 10-mM concentration of 5-ALA with PDT treatment increased the pan-caspase activity in the pigmented B16F10 melanoma cells, whereas 5 mM 5-ALA did not modify the enzymatic activity of the amelanotic B16G4F cell line. The disappearance of pan-caspase activity was observed for higher 5-ALA concentrations (20 mM for B16F10 cells and 10 mM for B16G4F cells) and corresponded to cell lysis. The total caspase activity (evaluated with a fluorometer and expressed in relative units) was determined for both melanoma cell lines 24 h after various 5-ALA concentrations and PDT, with a peptide substrate recognized by all caspases (pan-caspase) together and in the presence of a specific inhibitor (ZVAD-CHO).

Expression of p53 and PUMA in B16F10 and B16G4F cell lines after PDT

We studied the well-known tumor suppressor p53 protein involved in cell cycle control and apoptosis induction upon stress stimuli (Fig. 3). A significant p53 expression was observed in the control B16F10 cell line; 24 h after PDT treatment, the p53 signal was enhanced with the addition of 10 mM 5-ALA but its level was reduced in the presence of 20 mM 5-ALA. In contrast, no or a faint p53 expression was observed in the non-pigmented B16G4F cells regardless of the conditions (control, 5 and 10 mM 5-ALA treatment). Results of the PUMA analysis, one of the p53 transcriptional targets implicated in executive apoptosis, confirmed the findings concerning p53. PUMA expression in the pigmented B16F10 cells was correlated to that of p53 and in non-pigmented B16G4F cells only a faint PUMA band was detected.

Figure 3

Western blot analysis of p53 and PUMA expression after PDT with 5-ALA in B16F10 and B16G4F melanoma cells. An increase in p53 and PUMA expression was observed 24 h after 10 mM 5-ALA and PDT treatment of B16F10 melanoma, but no significant changes in expression in the B16G4F cell line was detected regardless of the condition. Cell lysates were realized 24 h after 5-ALA and light exposure, they were separated by SDS-PAGE and analyzed by western blotting with appropriate antibodies.

Expression of beclin-1, LC3-I, LC3-II and cathepsin-B after photodynamic treatment with 5-ALA

We studied the eventual activation of an autophagic signaling, through the expression of beclin-1, a regulator activated upstream, LC3-I and LC3-II which is implied in the nucleation of autophagosome and a lysosomal protein cathepsin B which concludes the autophagic process (Fig. 4). In control pigmented B16F10 cells, a moderate signal was detected for both beclin-1, LC3-I and II and cathepsin-B, which disappeared in the treated cells. Conversely, their expression was significantly increased in the control non-pigmented B16G4F cells and was reduced at a higher 5-ALA concentration (10 mM).

Figure 4

Western blot analysis of beclin-1, LC3-I, LC3-II and cathepsin-B expression after PDT with 5-ALA in B16F10 and B16G4F melanoma cells. Slight changes in beclin-1, LC3-I, LC3-II and cathepsin B expression were observed following 5-ALA and PDT treatment of B16F10 melanoma, whereas in the amelanotic B16G4F cell line autophagic markers were clearly enhanced after 5 mM 5-ALA and PDT, but were significantly reduced for the photocytotoxic 10 mM 5-ALA treatment. Cell lysates were realized 24 h after 5-ALA and light exposure, they were separated by SDS-PAGE and analyzed by western blotting with appropriate antibodies.

Discussion

Photodynamic therapy (PDT) is now a well-established treatment modality for cutaneous carcinomas camptothecin (1,5), but melanotic melanomas generally have a poor response to PDT owing to several characteristics that confer chemoresistance such as high antioxidant activity (2). The presence of melanin permits the absorption of UV and spectral light by pigmented melanoma, reducing photosensitizer excitation. The cell death pathway induced appears to differ in both according to photosensitizer, the cell type and in the case of melanoma with the presence of melanin. Thus, we studied the type of signaling pathway induced (apoptosis and autophagy) by 5-ALA, a physiologic compound currently used in vivo for various types of tumors, excited with a red illumination on the well-known mouse melanoma cell line B16F10 and its amelanotic variant B16G4F cells.

As expected, the 5-ALA molecule showed a similar and moderate toxicity in both pigmented and amelanotic cells. At almost all 5-ALA concentrations and after a 48-h treatment, cell growth was reinitiated concomitant with a recycling process. After 24 h, the 5-ALA photocytotoxicity varied as a function of the presence of melanin in the melanoma cells, and when the decrease in mitochondrial activity was moderate due to a repair process, this permitted a partial restoration of cell growth after 48 h. The slight reduction in dehydrogenase activity in the presence of low 5-ALA concentrations was noted in the two melanoma cell lines (pigmented or not), then the restart of cell growth was observed at 48 h, which was consistent with an autophagic process. Due to the high reactivity of photogenerated ROS, autophagy is initiated to remove oxidative damaged organelles such as mitochondria which are targets of 5-ALA (5,6). The 10 mM concentration of 5-ALA induced photocytotoxicity in B16F10 cells slightly weaker than that observed in the B16G4F amelanotic cells treated with 5 mM 5-ALA. Several studies have previously demonstrated that the presence of melanin in melanoma reduces drug photocytotoxicity. Ma et al(7) showed that violet light PDT was able to bleach melanin in melanotic tumors and therefore increase their sensitivity to red light PDT. The hypericin photocytoxicity toward pigmented UCT MEL-1 melanoma cells was found to be lower than that in unpigmented A375 melanoma, due to the protective properties of melanin on ROS (8). Recently, Mroz et al(9) reported the effectiveness of Photofrin and bacteriochlorin 3 in relation to the melanin content of B16 melanoma cells. The effectiveness of Photofrin to induce cell death was completely abolished in B16F10 cells with a high pigment content.

Many pathways have been discovered whereby mammalian cells execute cell death in response to PDT with different photosensitizers (10). The porphyrin family molecules such as 5-ALA are localized in mitochondria. After PDT treatment they induce ROS generation as described in numerous studies (6,11) and mainly produce a mitochondrial apoptosis with caspase activation. The moderate pan-caspase activity in pigmented B16F10 cells treated with 10 mM 5-ALA was compatible with mitochondrial apoptosis with caspase activation such as described by Buytaert et al(5). Radzi et al(12) in the same-pigmented cells irradiated in the presence of indocyanine green observed a caspase-independent apoptosis. This is similar to the type of death that we observed in amelanotic variant B16G4F cells by 5-ALA.

Western blot analysis of p53 and PUMA (one of its transcriptional targets) confirmed that in the presence of melanin in the B16F10 melanoma cells a caspase-dependent apoptosis was recruited. Data support the contribution of a p53-regulated response to PDT in cells expressing wild-type p53 as described (13). In the amelanotic variant B16G4F, no p53 and PUMA signals were detected, suggesting that the mitochondrial pathway was not activated. Prasad et al(14) showed that in 7 patients with desmoplastic melanoma (0.1% of cutaneous melanoma) characterized by the presence of amelanotic invasive spindle cells, 6 patients had an aberrant or null p53 expression. The absence of p53 and PUMA expression with caspase-independent signaling was supported by results indicating a role of a p53-independent mechanism in response to PDT in p53-deficient cells (13). Both apoptosis and autophagy can occur after PDT (15), and recent studies described a non-apoptotic cell death associated with the induction of autophagy (2,3,15,16).

In the B16F10 melanoma cell line our results showed that the absence of expression of an autophagic marker (beclin-1, LC3-I and LC3-II, cathepsin B) was in line with a mitochondrial caspase-dependent apoptosis. This mitochondrial death has been described in several melanoma cell lines treated with PDT and molecules of 5-ALA (6,17). On the other hand, in the amelanotic variant B16G4F cells, PDT treatment with 5-ALA led to the activiation of autophagy as described using the same photosensitizer in non-pigmented cells such as skin keratinocytes (18), PC12 and CL1-0 cells (3). The recycling process can lead to cell death when cells attempt to recycle damaged constituents beyond their capacity for recovery or in apoptosis-incompetent cells (15,19).

In summary, we demonstrated that 5-ALA and PDT with red illumination induced a differential susceptibility in melanoma cells based on the presence of melanin. In addition, mitochondrial apoptotic signaling was activated in the pigmented B16F10 cells, whereas an autophagic process leading to caspase-independent cell death occurred in amelanotic B16G4F cells. Further studies may confirm the attribution of PDT sensitivity of B16G4F cells to the lack of melanin and/or a p53 gene mutation.

Acknowledgements

We would like to thank Dr Cornelia Wilson-Whelan (University of Limoges) for the critical language editing of the manuscript, Tan Ouk and Anne-Sophie Rigaudeau for their technical advice.

References

1 

Choudhary S, Nouri K and Elsaie ML: Photodynamic therapy in dermatology: a review. Lasers Med Sci. 24:971–980. 2009. View Article : Google Scholar

2 

Davids LM and Kleemann B: Combating melanoma: the use of photodynamic therapy as a novel, adjuvant therapeutic tool. Cancer Treat Rev. 37:465–475. 2011.PubMed/NCBI

3 

Ji HT, Chien LT, Lin YH, et al: 5-ALA-mediated photodynamic therapy induces autophagic cell death via AMP-activated protein kinase. Mol Cancer. 9:912010. View Article : Google Scholar : PubMed/NCBI

4 

Zuliani T, Duval R, Jayat C, et al: Sensitive and reliable JC-1 and TOTO-3 double staining to assess mitochondrial transmembrane potential and plasma membrane integrity: interest for cell death investigations. Cytometry A. 54:100–108. 2003. View Article : Google Scholar

5 

Buytaert E, Dewaele M and Agostinis P: Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta. 1776:86–107. 2007.PubMed/NCBI

6 

Krestyn E, Kolarova H, Bajgar R, et al: Photodynamic properties of ZnTPPS(4), ClAlPcS(2) and ALA in human melanoma G361 cells. Toxicol In Vitro. 24:286–291. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Ma LW, Nielsen KP, Iani V, et al: A new method for photodynamic therapy of melanotic melanoma - effects of depigmentation with violet light photodynamic therapy. J Environ Pathol Toxicol Oncol. 26:165–172. 2007. View Article : Google Scholar : PubMed/NCBI

8 

Davids LM, Kleemann B, Kacerovská D, et al: Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B. 91:67–76. 2008. View Article : Google Scholar : PubMed/NCBI

9 

Mroz P, Huang YY, Szokalska A, et al: Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy. FASEB J. 24:3160–3170. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Robertson CA, Evans DH and Abrahamse H: Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B. 96:1–8. 2009. View Article : Google Scholar : PubMed/NCBI

11 

Kästle M, Grimm S, Nagel R, et al: Combination of PDT and inhibitor treatment affects melanoma cells and spares keratinocytes. Free Radic Biol Med. 50:305–312. 2011.PubMed/NCBI

12 

Radzi R, Osaki T, Tsuka T, et al: Photodynamic hyperthermal therapy with indocyanine green (ICG) induces apoptosis and cell cycle arrest in B16F10 murine melanoma cells. J Vet Med Sci. 74:545–551. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Zawacka-Pankau J, Krachulec J, Grulkowski I, et al: The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances. Toxicol Appl Pharmacol. 232:487–497. 2008. View Article : Google Scholar : PubMed/NCBI

14 

Prasad ML, Patel SG and Busam KJ: Primary mucosal desmoplastic melanoma of the head and neck. Head Neck. 26:373–377. 2004. View Article : Google Scholar : PubMed/NCBI

15 

Kessel D and Oleinick NL: Initiation of autophagy by photodynamic therapy. Methods Enzymol. 431:1–16. 2009. View Article : Google Scholar

16 

François A, Marchal S, Guillemin F, et al: mTHPC-based photodynamic therapy induction of autophagy and apoptosis in cultured cells in relation to mitochondria and endoplasmic reticulum stress. Int J Oncol. 39:1537–1543. 2011.PubMed/NCBI

17 

Tsai T, Ji HT, Chiang PC, et al: ALA-PDT results in phenotypic changes and decreased cellular invasion in surviving cancer cells. Lasers Surg Med. 41:305–315. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Silva JN, Galmiche A, Tomé JP, et al: Chain-dependent photocytotoxicity of tricationic porphyrin conjugates and related mechanisms of cell death in proliferating human skin keratinocytes. Biochem Pharmacol. 80:1373–1385. 2010. View Article : Google Scholar

19 

Reiners JJ, Agostinis P, Berg K, et al: Assessing autophagy in the context of photodynamic therapy. Autophagy. 6:7–18. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Sparsa A, Bellaton S, Naves T, Jauberteau M, Bonnetblanc J, Sol V, Verdier M and Ratinaud M: Photodynamic treatment induces cell death by apoptosis or autophagy depending on the melanin content in two B16 melanoma cell lines. Oncol Rep 29: 1196-1200, 2013.
APA
Sparsa, A., Bellaton, S., Naves, T., Jauberteau, M., Bonnetblanc, J., Sol, V. ... Ratinaud, M. (2013). Photodynamic treatment induces cell death by apoptosis or autophagy depending on the melanin content in two B16 melanoma cell lines. Oncology Reports, 29, 1196-1200. https://doi.org/10.3892/or.2012.2190
MLA
Sparsa, A., Bellaton, S., Naves, T., Jauberteau, M., Bonnetblanc, J., Sol, V., Verdier, M., Ratinaud, M."Photodynamic treatment induces cell death by apoptosis or autophagy depending on the melanin content in two B16 melanoma cell lines". Oncology Reports 29.3 (2013): 1196-1200.
Chicago
Sparsa, A., Bellaton, S., Naves, T., Jauberteau, M., Bonnetblanc, J., Sol, V., Verdier, M., Ratinaud, M."Photodynamic treatment induces cell death by apoptosis or autophagy depending on the melanin content in two B16 melanoma cell lines". Oncology Reports 29, no. 3 (2013): 1196-1200. https://doi.org/10.3892/or.2012.2190
Copy and paste a formatted citation
x
Spandidos Publications style
Sparsa A, Bellaton S, Naves T, Jauberteau M, Bonnetblanc J, Sol V, Verdier M and Ratinaud M: Photodynamic treatment induces cell death by apoptosis or autophagy depending on the melanin content in two B16 melanoma cell lines. Oncol Rep 29: 1196-1200, 2013.
APA
Sparsa, A., Bellaton, S., Naves, T., Jauberteau, M., Bonnetblanc, J., Sol, V. ... Ratinaud, M. (2013). Photodynamic treatment induces cell death by apoptosis or autophagy depending on the melanin content in two B16 melanoma cell lines. Oncology Reports, 29, 1196-1200. https://doi.org/10.3892/or.2012.2190
MLA
Sparsa, A., Bellaton, S., Naves, T., Jauberteau, M., Bonnetblanc, J., Sol, V., Verdier, M., Ratinaud, M."Photodynamic treatment induces cell death by apoptosis or autophagy depending on the melanin content in two B16 melanoma cell lines". Oncology Reports 29.3 (2013): 1196-1200.
Chicago
Sparsa, A., Bellaton, S., Naves, T., Jauberteau, M., Bonnetblanc, J., Sol, V., Verdier, M., Ratinaud, M."Photodynamic treatment induces cell death by apoptosis or autophagy depending on the melanin content in two B16 melanoma cell lines". Oncology Reports 29, no. 3 (2013): 1196-1200. https://doi.org/10.3892/or.2012.2190
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team